NephroDI Therapeutics, Inc.
NephroDI Therapeutics is a pharmaceutical company focusing on concentration disorders of the kidney, specifically developing an oral drug to treat Nephrogenic Diabetes Insipidus (NDI) in children. The company is dedicated to addressing unmet medical challenges related to NDI, a rare genetic kidney disorder that causes excessive urine production and severe dehydration, impacting children's health and quality of life. Their mission is to develop first-in-class therapies, leveraging novel AMPK activators, to improve outcomes for patients with NDI.
Industries
Nr. of Employees
small (1-50)
NephroDI Therapeutics, Inc.
Products
Kidney-targeted small-molecule AMPK activator (clinical candidate)
A small-molecule AMPK activator engineered for kidney targeting under development as a potential first-in-class therapy to improve urine-concentrating ability in congenital nephrogenic diabetes insipidus.
Kidney-targeted small-molecule AMPK activator (clinical candidate)
A small-molecule AMPK activator engineered for kidney targeting under development as a potential first-in-class therapy to improve urine-concentrating ability in congenital nephrogenic diabetes insipidus.
Services
Collaborative clinical development and licensing partnerships
Strategic partnerships to co-develop clinical studies and potentially license or expand development of clinical-stage kidney-targeted therapeutics.
Collaborative clinical development and licensing partnerships
Strategic partnerships to co-develop clinical studies and potentially license or expand development of clinical-stage kidney-targeted therapeutics.
Expertise Areas
- Drug discovery for kidney concentration disorders
- Preclinical efficacy and pharmacology
- Renal physiology and molecular mechanisms
- Clinical development for rare pediatric renal diseases
Key Technologies
- AMPK activator small molecules
- Kidney-targeted small-molecule design
- In vivo rodent models of nephrogenic diabetes insipidus
- Preclinical pharmacology and safety profiling